Immunomedics, Inc. (NASDAQ:IMMU) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Friday.

Other analysts have also issued research reports about the company. Jefferies Group LLC set a $8.00 target price on Immunomedics and gave the stock a “buy” rating in a research note on Thursday, April 20th. Zacks Investment Research upgraded Immunomedics from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a research note on Monday, July 17th. ValuEngine upgraded Immunomedics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Cowen and Company reiterated an “outperform” rating and issued a $15.00 target price on shares of Immunomedics in a research note on Monday, July 24th. Finally, Wells Fargo & Company upgraded Immunomedics from a “market perform” rating to an “outperform” rating in a research note on Friday, May 5th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $12.00.

Shares of Immunomedics (IMMU) traded up 2.00% on Friday, reaching $8.16. 1,971,395 shares of the company traded hands. The stock’s market capitalization is $894.37 million. The stock’s 50 day moving average price is $8.56 and its 200-day moving average price is $6.62. Immunomedics has a one year low of $2.02 and a one year high of $9.51.

WARNING: This story was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/04/bidaskclub-lowers-immunomedics-inc-immu-to-hold.html.

Institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc raised its position in shares of Immunomedics by 7.4% in the second quarter. Legal & General Group Plc now owns 25,477 shares of the biopharmaceutical company’s stock valued at $222,000 after buying an additional 1,747 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its position in shares of Immunomedics by 3.7% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 66,049 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 2,384 shares in the last quarter. Creative Planning raised its position in shares of Immunomedics by 1.7% in the second quarter. Creative Planning now owns 179,130 shares of the biopharmaceutical company’s stock valued at $1,582,000 after buying an additional 3,065 shares in the last quarter. Teachers Advisors LLC raised its position in shares of Immunomedics by 2.1% in the first quarter. Teachers Advisors LLC now owns 189,537 shares of the biopharmaceutical company’s stock valued at $1,226,000 after buying an additional 3,876 shares in the last quarter. Finally, HighTower Advisors LLC raised its position in shares of Immunomedics by 13.8% in the first quarter. HighTower Advisors LLC now owns 58,115 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 7,050 shares in the last quarter. Hedge funds and other institutional investors own 62.01% of the company’s stock.

Immunomedics Company Profile

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.